Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Asthma
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Related Questions
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
Is methacholine challenge on its way out?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
